| Autor: |
Fahimeh Vahabizad, Mansoureh Togha, Shadi Ariyanfar, Mohammad-Reza Fattahi, Samaneh Haghighi, Zahra Ebadi, Sanaz Ahmadi Karvigh, Sara Heidari, Maryam Shafaei, Hale Ashraf, Azar Haddadi, Mohammad Talebpour, Arash Safaei, Hoda Asefi |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Acta neurologica Belgica. |
| ISSN: |
2240-2993 |
| Popis: |
Since the beginning of the COVID-19 pandemic, a number of COVID-related neurological manifestations have been reported. We aimed to categorize the features of hospitalized COVID-19 patients who experienced neurological symptoms.In this descriptive, cross-sectional study, we enrolled all patients hospitalized with COVID-19 who experienced neurological symptoms in two hospitals in Tehran. Diagnosis of COVID-19 was established by PCR tests or computed tomography of the chest combined with COVID-19 clinical findings. The clinical characteristics, laboratory data, and imaging findings from 365 patients were analyzed.The average patient age was 59.2 ± 16.7 years and included 213 males and 152 females. The most prevalent neurological symptoms were headache (56.2%), impaired consciousness (55%), and dizziness (20.5%). During hospitalization, most of the patients did not require mechanical ventilation (81.9%). The percentage of patients with end-organ damage was 9% and mortality was 15%. Regression analysis on the neurological symptoms indicated that the mortality rate of patients with headaches was 84% lower than for the other neurological symptoms. Hyperglycemia was significantly related with end-organ damage and mortality (p = 0.029, p = 0.08, respectively). New vascular lesions were evident on brain MRIs of 9 patients and brain CTs of 16 patients.Among the neurological symptoms of patients with COVID-19, headache appeared to indicate a protective factor against development of end-organ damage as well as mortality. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink